Integrated 1
Integrated 1-13497
Down syndrome
Nuchal Translucency (NT)
PAPP-A
Screening test for Open Spina Bifida/ONTD, Trisomy 21/Down syndrome and Trisomy 18/Edward's syndrome
Integrated screening requires two specimens: one collected in the first trimester and one in the second trimester.
- Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood
- Collect between 10.0 and 13.9 weeks gestation
- Immediatley following collection, mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
Pour off/aliquoting is not advised
Gold serum separator (SST) tube
- Fetal nuchal translucency (NT) measurement
- The NT measurement must be performed by a sonographer credentialed by the Fetal Medicine Foundation or other equivalent entity. The sonographer's credential/certification number must be provided.
- Crown rump length measurement
- Patient's race
- Patient's weight
- Patient's date of birth
- Patient's insulin dependent diabetic status
- Number of fetuses
- Patient history (ie, prior Down syndrome pregnancy, ultrasound anomalies).
Complete information is necessary to interpret the test
Maternal testing clinical information form
Gestational age conversions:
Ambient (preferred) - 7 days
Refrigerated - 14 days
Frozen - 14 days
Freeze/thaw cycles - stable x 3
- Gross hemolysis
- Gross lipemia
- Quantity not sufficient for analysis (QNS)
- Improper specimen type
Chemiluminescent immunoassay
An interpretive report will be provided
There is no risk assessment after the first draw. A specimen for the Integrated 2 must be collected and the overall risk for Down syndrome, trisomy 18 and open spina bifida is provided after the testing of the second blood sample, using information from the part 1 and part 2.
Serum testing is provided from 10.0 to 13.9 weeks of gestation. NT can be assessed when the CRL is 45 to 84 mm.